Skip to main content
. 2022 Nov 4;5(11):e2240145. doi: 10.1001/jamanetworkopen.2022.40145

Figure 4. Comparison of 4-Factor Plasma Concentrate Complex (4F-PCC) vs Andexanet Alfa (AA) for Proportion of Anticoagulation Reversed, Mortality, and Thromboembolic Outcomes Among Patients Receiving Factor Xa Inhibitors With Intracranial Hemorrhage.

Figure 4.